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1 |  INTRODUCTION
By using genome‐wide analysis, in 2003 a microdeletion 
in the 2q23.1 region was for the first time identified by 
Vissers and co‐workers in a 12‐year old girl, out of a series 
of 20 patients with unexplained intellectual disability and 
additional malformations such as microcephaly and facial 
dysmorphisms. They suggested that one or more genes 
within the deleted region could be causative for the pheno-
type (Vissers et al., 2003). In subsequent years it became 
obvious that the minimal critical region in the 2q23.1 dele-
tion in a group of 15 patients comprises one gene only, that 
is methyl‐CpG‐binding domain protein 5 (MBD5) [OMIM: 
*611472] which is a member of the methyl‐CpG‐binding 
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Abstract
Background: The minimal critical region in 2q23.1 deletion syndrome comprises 
one gene only, that is, the methyl‐CpG‐binding domain protein 5 (MBD5) gene. 
Since the phenotypes of patients with deletions, duplications or pathogenic variants 
of MBD5 show considerable overlap, the term MBD5‐associated neurodevelopmen-
tal disorder (MAND) was proposed. These syndromes are characterized by intel-
lectual disability, seizures of any kind and symptoms from the autism spectrum. In a 
very limited number of patients, MAND may be associated with regression starting 
either at early infancy or at midlife.
Methods: The present paper describes a severely intellectually disabled autistic fe-
male with therapy resistant complex partial epilepsy starting at her 16the with grad-
ual cognitive and behavioral regression towards her sixth decade.
Results: Cognitive and behavioral regression occurred towards the patient's sixth 
decade. Exome sequencing disclosed a novel heterozygous pathogenic frameshift 
mutation of MBD5 that was considered to be causative for the combination of intel-
lectual disability, treatment‐resistant epilepsy and autism.
Conclusion: The presented patient is the second with a pathogenic MBD5 mutation 
in whom the course of disease is suggestive of early onset dementia starting in her 
fifth decade. These findings stress the importance of exome sequencing, also in el-
derly intellectually disabled patients, particularly in those with autism.
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domain protein family that also includes MECP2, the caus-
ative locus in Rett syndrome, and is demonstrated to be 
highly expressed in the brain, fetal testes and fetal ovaries 
(Van Bon et al., 2010; Laget et al., 2010). The major char-
acteristics of patients with a deletion comprising MBD5 are 
moderate to severe intellectual disability, seizures, sleep dis-
turbances, speech impairment, autistic‐like symptoms and 
behavioral problems. In addition, a broad range of dysmor-
phisms as well as somatic abnormalities such as constipa-
tion and hand/foot anomalies may be present (Van Bon et al., 
2010; Bonnet et al., 2013; Talkowski et al., 2011; Williams 
et al., 2010). Interestingly, a great overlap has been observed 
in clinical characteristics between patients with a deletion 
or duplication of 2q23.1 and MBD5 point mutations, in that 
they all share developmental and motor delay, language im-
pairment, behavioral problems and symptoms from the au-
tism spectrum albeit that the 2q23.1 duplication syndrome 
seems to have a milder phenotype. In contrast to those with 
a mutation, MBD5‐specific deletion or 2q23.1 deletion, sei-
zures are not common in patients with MBD5 duplications. 
These observations suggest that MBD5 can be considered as 
a dose‐sensitive gene for normal development and plays a 
pivotal role in the pathophysiology of autism spectrum dis-
order (Mullegama et al., 2014).
Since the phenotypes of patients with deletions, dupli-
cations or pathogenic variants of MBD5 show considerable 
overlap, the umbrella term MBD5‐associated neurodevel-
opmental disorder (MAND; OMIM: #156200) was pro-
posed to describe a group of syndromes that is caused by 
haploinsufficiency of MBD5 (Mullegama & Elsea, 2016). 
These syndromes are characterized by intellectual disability 
with serious developmental delays, language impairment, 
symptoms from the autism spectrum, sleep disturbances, 
and seizures of any kind although most patients exhibit one 
seizure type only. It is assumed that the sleep disturbances 
originate from MBD5‐ associated dysregulation of the cir-
cadian rhythm pathway (Mullegama, Pugliesi, et al., 2015). 
Albeit that MAND is suggested to be consistent with nor-
mal lifespan, in some patients it may be associated with 
regression starting either at early infancy as described in 
two single case reports of female children (Chung et al., 
2011; Noh & Graham, 2012) or at midlife as mentioned 
in the paper by Hodge et al. (2014). The latter concerned 
a 44‐year‐old male patient with early onset dementia, cat-
aracts and behavioral regression with increase in autistic‐
like symptoms without, however, a detailed description of 
the disease history.
In this paper we describe a severely intellectually dis-
abled autistic female with therapy resistant complex partial 
epilepsy starting at the age of 16, who developed cognitive 
and behavioral regression in her fifth decade and in whom 
ultimately exome sequencing disclosed a novel heterozygous 
pathogenic frameshift mutation in MBD5.
2 |  CASE REPORT
The patient was a 60‐year‐old intellectually disabled female 
born from nonconsanguineous parents. Because of immi-
nent miscarriage, her mother was treated with diethylstil-
bestrol during pregnancy. She was born after a pregnancy of 
6,5 months with a birth weight of 1,500 grams and has one 
younger and one older healthy brother. Early development 
was characterized by global delay especially concerning psy-
chomotor skills. Due to a dysfunctional pedagogic climate 
with poor mother‐child attachment and alcohol abuse of both 
parents, already in her first years, severe oppositional behav-
ioral problems became prominent that necessitated institu-
tionalization at the age of four.
During subsequent years, the patient stayed in various 
institutes for intellectually disabled persons and sheltered 
home facilities but returned several times to her parental 
home because of lack of social interactions with her peers. 
At age 16, complex partial epileptic seizures occurred in 
combination with sleep disturbances and affective flatten-
ing for which she was admitted to a specialized hospital for 
epilepsy. Treatment with antiepileptics was started. She 
followed special education until her twenties and was em-
ployed on a part‐time basis for about five years in a shel-
tered work setting. Over the years, she alternately stayed 
at her parent's home until her mother became seriously ill 
and deceased, aged 65, from lung carcinoma and liver cir-
rhosis. At that time, the patient was 34 years. During that 
time, her younger brother developed a psychotic disorder 
for which he had to be admitted to a psychiatric hospital, 
was treated with depot antipsychotics and stayed thereaf-
ter for many years under outpatient control. In the mean-
time, the alcohol abuse of her father became increasingly 
problematic. Because of these circumstances, permanent 
institutionalization became necessary with, however, fre-
quent changes in daycare settings because of mismatch 
between her needs and behavioral repertoire. Also, in this 
year, her father died at the age of 76 from acute cardiac 
failure.
In the following years the patient developed diabe-
tes mellitus type 2, psoriasis vulgaris, hypertension and 
constipation for which adequate medications were pre-
scribed. In addition, bilateral mild cataract was diagnosed. 
During this period, she was hospitalized several times 
because of her complex partial epilepsy that, however, 
persisted despite treatment with various combinations of 
antiepileptics, including valproic acid, levetiracetam, car-
bamazepine, clobazam and vigabatrine. At the age of 54, 
EEG‐recording showed multifocal epileptic features with 
spike‐wave configurations predominantly in the left fron-
tal‐temporal region. MRI‐scanning of the brain disclosed 
no abnormalities apart from possibly rather pronounced 
folia of the cerebellar vermis. Testing of intelligence by 
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WISC‐III administration resulted in a developmental age of 
about 9 years. Gradual decline of cognitive and behavioral 
functioning in the presence of enduring seizures and mood 
instability led, at age 60, to specialized neuropsychiatric 
consultation.
At referral, the patient was treated with the antiepi-
leptics carbamazepine (600  mg; 7.6  mg/L), valproic acid 
(1,500 mg; 44 mg/L) and clobazam (10 mg; <50/520 µgr/L) 
whereas her somatic medications included metformine 
500 mg daily, lisinopril 5 mg daily and macrogol in variable 
dose. In addition, for behavioral control and enduring sleep 
disturbances with frequent awakenings, 2 mg/day haloper-
idol and 100  mg/day sertraline were given that, however, 
were discontinued shortly after referral because of lack of 
effect and very low plasma concentrations due to interaction 
with carbamazepine.
Somatic investigation disclosed a full nasal tip but no 
other dysmorphisms (Figure 1). Height, weight and head cir-
cumference were 157 cm (−2,3 SD), 53 kg (BMI: 21,5) and 
53 cm (−1,3 SD), respectively. Neuropsychiatric examination 
revealed autistic behaviors with echolalia and perseverations 
as well as lack of initiative and low responsiveness. No neu-
rological abnormalities could be detected although absences 
were regularly observed. No reliable WISC‐V scores could 
be obtained because of floor effects for most subtests. As as-
sessed with the Vineland Adaptive Behavior Scale (De Bildt 
& Kraijer, 2003), for the factors communication, daily perfor-
mance and socialization, a developmental age of 5;3, 3;8 and 
3;9 (years;months), respectively, was established that were 
all clearly lower as compared to the results at the age of 56 
(6;11, 6;11 and 5;1 year;months, respectively) confirming the 
observed decline in general functioning over the past years. 
By using the Dutch Scale for Emotional Development in peo-
ple with intellectual disability (SEO‐R; Claes & Verduyn, 
2012), her emotional developmental age was established 
to be maximally 18–24  months. With the AVZ‐R (Kraijer, 
2004), a validated Dutch rating scale covering the autism pa-
rameters social, communicative and stereotyped behavior, a 
total score of 7 was established (range 0–19; scores 0–6 ab-
sent, 7–9 possible, 10–19 autism/pdd), indicative for possible 
autism. With the Autism Diagnostic Observation Schedule 
(ADOS‐2; De Bildt, Jonge, & Greaves‐Lord, 2013), a total 
score of 21 (cut‐off score = 10) corroborated a diagnosis of 
autism. Hematological and biochemical parameters were all 
within normal range. Earlier performed SNP array analysis 
did not show any abnormalities.
For reevaluation of her epilepsy, possible adjustment of an-
tiepileptic medication and high‐resolution MRI‐scanning, the 
patient was referred to the Academic Centre for Epileptology 
Kempenhaeghe. As depicted in Figure 2, 24‐hr video‐EEG 
recording demonstrated sporadic left frontotemporal spike‐
wave configurations (both awake and during relaxation and 
falling asleep). No changes in the combination of antiepilep-
tics were judged necessary. MRI‐scanning of the brain under 
general anesthesia disclosed, comparable to the aforemen-
tioned MRI, no abnormalities (Figure 3). For further etiolog-
ical analysis, whole exome sequencing was performed and 
subsequent analysis of variants within a panel of known intel-
lectual disability disease genes resulted in the detection of a 
novel heterozygous pathogenic frameshift mutation in exon 9 
of MBD5 (NG_017003.2) that leads to a premature stop codon 
within that same exon. The frameshift mutation concerns: 
Chr2(GRCh37):g.149227685del; NM_018328.4:c.2173del 
(p.[Ala725fs]). This finding was considered to be pathogenic 
and causative for the combination of intellectual disability, 
autism and treatment‐resistant epilepsy.
3 |  DISCUSSION
In this paper, a detailed description of an older intellectually 
disabled autistic female with MBD5‐associated neurode-
velopmental disorder caused by a not previously described 
heterozygous frameshift mutation in MBD5 is given. Her 
phenotypical characteristics closely match the previously de-
scribed behavioral, somatic and neurological MAND‐profile 
(Mullegama & Elsea, 2016; Talkowski et al., 2011; Williams 
et al., 2010). Interestingly, this is the first patient in whom, 
apart from therapy resistant complex partial epilepsy, gradual 
regression occurred towards her sixth decade that could be 
objectivated with psychological and behavioral assessments.
With respect to brain imaging, no abnormalities could be 
detected either aged 54 or six years later. As to intellectual 
and cognitive function, however, six years before referral, the 
level of developmental was established to be about nine years 
whereas at referral she was no longer eligible for testing. This 
apparent deterioration was corroborated by several parame-
ters as measured by the Vineland scales, that is, a significant 
F I G U R E  1  Picture of the face of the patient without remarkable 
dysmorphisms, apart from slight microcephaly
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decrease of especially daily performance skills and socializa-
tion. These converging observations are suggestive of early 
onset dementia.
The clinical features of MBD5 disruption with associ-
ated neurodevelopmental disorder and autism show similar-
ities with other genetic syndromes such as Smith–Magenis, 
Rubinstein–Taybi, Angelman, Prader–Willi, Kleefstra and 
Pitt–Hopkins (Hodge et al., 2014; Mullegama, Alaimo, 
Chen, & Elsea, 2015). Indeed, network pathway analysis 
of nine ASD‐associated neurodevelopmental disorders dis-
closed that MBD5 regulates the expression of several au-
tism related genes (UBE3A, TCF4, MEF2C, EHMT1, and 
RAI1) and that these and other genes (e.g., MECP2 and 
KMT2D) may combine into common or overlapping net-
work pathways with phenotypical similarity (Mullegama, 
Alaimo, et al., 2015). This kind of functional convergence 
may be a key contributor to the identification of candidate 
genes and specific pharmacological interventions (Gigek 
et al., 2015; Iwase et al., 2017; Kleefstra et al., 2012; 
Koemans et al., 2017).
Summarizing, in the presented patient a diagnosis of 
MAND was established caused by a novel pathogenic muta-
tion in MBD5. She is the second in whom the course of dis-
ease is suggestive of early onset dementia developing in the 
fifth decade. These findings stress both the clinical and scien-
tific importance of exome sequencing techniques in patients 
with intellectual disability and psychopathology, particularly 
syndromes from the autism spectrum.
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